Company · CIK 0001335105 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
LIXTE BIOTECHNOLOGY HOLDINGS, INC. · NMAD
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 AForm 4 → | Jul 2, 4:18 pm EDT | Peter StazzoneChief Financial Officer | 50,000 | — | — | 100,000 | — | |
| Jul 1, 2026 AForm 4 → | Jul 2, 4:16 pm EDT | Jason David SawyerDirector | 40,000 | — | — | 65,000 | — | |
| Jul 1, 2026 AForm 4 → | Jul 2, 4:13 pm EDT | Geordan Garrett PursgloveCEO and Chairman of the Board, Director | 350,000 | — | — | 700,000 | — | |
| Jul 1, 2026 AForm 4 → | Jul 2, 4:11 pm EDT | Guy Warren PrimusDirector | 15,000 | — | — | 40,000 | — | |
| Jul 1, 2026 AForm 4 → | Jul 2, 4:10 pm EDT | Michael Andrew HollowayDirector | 15,000 | — | — | 40,000 | — | |
| Jul 1, 2026 AForm 4 → | Jul 2, 4:08 pm EDT | Lourdes FelixDirector | 30,000 | — | — | 55,000 | — |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.